{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:37:10Z","timestamp":1791380230955,"version":"4.3.3"},"reference-count":38,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Objective: Posttraumatic Stress Disorder (PTSD) is a common condition with few effective medication treatments. Glecaprevir\/Pibrentasvir (GLE\/PIB), a treatment for hepatitis C virus (HCV) infection, demonstrated possible evidence of effectiveness for PTSD in an epidemiological study. We sought to determine if GLE\/PIB decreases the symptoms of PTSD and modulates inflammation. Methods: An uncontrolled open trial was conducted at the Veterans Affairs Medical Center in White River Junction Vermont. Participants were veterans with PTSD and no HCV infection. Ten participants received Glecaprevir 100 mg\/Pibrentasvir 40 mg, three tablets daily for 8 weeks. Symptoms were measured at baseline, mid-treatment, post-treatment, as well as at three- and six-months post-treatment. The primary outcome was PTSD symptoms as measured by the Clinician Administered PTSD Scale for DSM 5 (CAPS-5). Exploratory analyses were conducted to assess serum inflammatory biomarkers at baseline and posttreatment. Results: The mean baseline CAPS-5 score was 33.6 (SD = 3.3). Six-month post-treatment effects were large (CAPS-5: d = 1.6, p &lt; 0.01). By the end of the study, eight patients met the criteria for response, including eight who met the criteria for loss of PTSD diagnosis and six who met the criteria for total remission of PTSD (CAPS-5 score of less than 12). Lower interleukin (IL)-27 levels prior to treatment were predictive of treatment response. Eight-week IL-9 levels changes with treatment were associated with symptom improvement. Conclusions: GLE\/PIB may be an effective treatment for PTSD. Furthermore, treatment may modulate inflammatory responses in PTSD. Future studies are required to confirm these findings regarding GLE\/PIB, PTSD, and inflammation. Psychopharmacology Bulletin. 2026;56(1):28\u201338.<\/jats:p>","DOI":"10.64719\/pb.15419","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:38:16Z","timestamp":1767976696000},"page":"28-38","source":"Crossref","is-referenced-by-count":1,"title":["Glecaprevir\/Pibrentasvir for Post Traumatic Stress Disorder"],"prefix":"10.64719","volume":"56","author":[{"given":"Bradley V.","family":"Watts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista D.","family":"Disano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal M.","family":"Noller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Rozema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Vincenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (5th edition) Ref Rev. 2014;28(3):36\u201337. doi: 10.1108\/RR-10-2013-0256.","DOI":"10.1108\/RR-10-2013-0256"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from wave 2 of the national epidemiologic survey on alcohol and related conditions. J Anxiety Disord. 2011;25(3):456\u2013465. doi: 10.1016\/j.janxdis.2010.11.010.","DOI":"10.1016\/j.janxdis.2010.11.010"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Goldstein RB, Smith SM, Chou SP et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the national epidemiologic survey on alcohol and related conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51(8):1137\u20131148. doi: 10.1007\/s00127-016-1208-5.","DOI":"10.1007\/s00127-016-1208-5"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Forehand JA, Peltzman T, Westgate CL, Riblet NB, Watts BV, Shiner B. Causes of excess mortality in veterans treated for posttraumatic stress disorder. Am J Prev Med. 2019;57(2):145\u2013152. doi: 10.1016\/j.amepre.2019.03.014.","DOI":"10.1016\/j.amepre.2019.03.014"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Schnurr PP, Hamblen JL, Wolf J et al. The management of posttraumatic stress disorder and acute stress disorder: synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2024;177(3):363\u2013374. doi: 10.7326\/M23-2757.","DOI":"10.7326\/M23-2757"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74(6):e541\u2013550. doi: 10.4088\/JCP.12r08225.","DOI":"10.4088\/JCP.12r08225"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Shiner B, Leonard C, Gui J et al. Measurement strategies for evidence-based antidepressants for posttraumatic stress disorder delivery: trends and associations with patient-reported outcomes. Adm Policy Ment Health. 2021;48(1):70\u201387. doi: 10.1007\/s10488-020-01047-w.","DOI":"10.1007\/s10488-020-01047-w"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Maguen S, Li Y, Madden E et al. Factors associated with completing evidence-based psychotherapy for PTSD among veterans in a national healthcare system. Psychiatry Res. 2019;274:112\u2013128. doi: 10.1016\/j.psychres.2019.02.027.","DOI":"10.1016\/j.psychres.2019.02.027"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Holder N, Shiner B, Li Y et al. Cognitive processing therapy for veterans with posttraumatic stress disorder: what is the median effective dose? J Affect Disord. 2020;273:425\u2013433. doi: 10.1016\/j.jad.2020.04.030.","DOI":"10.1016\/j.jad.2020.04.030"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Shiner BR, Gui J, Rozema L et al. Patient and clinical factors associated with response to medications for posttraumatic stress disorder. J Clin Psychiatry. 2021;82(6):21m13913. doi: 10.4088\/JCP.21m13913.","DOI":"10.4088\/JCP.21m13913"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Krystal JH, Davis LL, Neylan TC et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD psychopharmacology working group. Biol Psychiatry. 2017;82(7):e51\u2013e59. doi: 10.1016\/j.biopsych.2017.03.007.","DOI":"10.1016\/j.biopsych.2017.03.007"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Katrinli S, Oliveira NCS, Felger JC, Michopoulos V, Smith AK. The role of the immune system in posttraumatic stress disorder. Transl Psychiatry. 2022;12(1):313. doi: 10.1038\/s41398-022-02094-7.","DOI":"10.1038\/s41398-022-02094-7"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Wang Z, Caughron B, Young MRI. Posttraumatic stress disorder: an immunological disorder? Front Psychiatry. 2017;8:222. doi: 10.3389\/fpsyt.2017.00222.","DOI":"10.3389\/fpsyt.2017.00222"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Sumner JA, Chen Q, Roberts AL et al. Cross-sectional and longitudinal associations of chronic posttraumatic stress disorder with inflammatory and endothelial function markers in women. Biol Psychiatry. 2017;82(12):875\u2013884. doi: 10.1016\/j.biopsych.2017.06.020.","DOI":"10.1016\/j.biopsych.2017.06.020"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005;5(7):521\u2013531. doi: 10.1038\/nri1648.","DOI":"10.1038\/nri1648"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Pan X, Kaminga AC, Wu Wen S, Liu A. Chemokines in post-traumatic stress disorder: a network meta-analysis. Brain Behav Immun. 2021;92:115\u2013126. doi: 10.1016\/j.bbi.2020.11.033.","DOI":"10.1016\/j.bbi.2020.11.033"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Zhang L, Hu XZ, Li X et al. Potential chemokine biomarkers associated with PTSD onset, risk and resilience as well as stress responses in US military service members. Transl Psychiatry. 2020;10(1):31. doi: 10.1038\/s41398-020-0693-1.","DOI":"10.1038\/s41398-020-0693-1"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zheng ZH, Tu JL, Li XH et al. Neuroinflammation induces anxiety- and depressive-like behavior by modulating neuronal plasticity in the basolateral amygdala. Brain Behav Immun. 2021;91:505\u2013518. doi: 10.1016\/j.bbi.2020.11.007.","DOI":"10.1016\/j.bbi.2020.11.007"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Lima Giacobbo B, Doorduin J, Klein HC, Dierckx R, Bromberg E, De Vries EFJ. Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation. Mol Neurobiol. 2019;56(5):3295\u20133312. doi: 10.1007\/s12035-018-1283-6.","DOI":"10.1007\/s12035-018-1283-6"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016;139(S2):136\u2013153. doi: 10.1111\/jnc.13607.","DOI":"10.1111\/jnc.13607"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Yehuda R, Bierer LM, Pratchett LC et al. Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: randomized trial showing improved treatment retention and outcome. Psychoneuroendocrinology. 2015;51:589\u2013597. doi: 10.1016\/j.psyneuen.2014.08.004.","DOI":"10.1016\/j.psyneuen.2014.08.004"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Lehrner A, Hildebrandt T, Bierer LM et al. A randomized, double-blind, placebo-controlled trial of hydrocortisone augmentation of prolonged exposure for PTSD in U.S. combat veterans. Behav Res Ther. 2021;144:103924. doi: 10.1016\/j.brat.2021.103924.","DOI":"10.1016\/j.brat.2021.103924"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Shiner B, Forehand JA, Rozema L et al. Mining clinical data for novel posttraumatic stress disorder medications. Biol Psychiatry. 2022;91(7):647\u2013657. doi: 10.1016\/j.biopsych.2021.10.008.","DOI":"10.1016\/j.biopsych.2021.10.008"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Shiner B, Huybrechts K, Gui J et al. Comparative effectiveness of direct-acting antivirals for posttraumatic stress disorder in veterans affairs patients with hepatitis C virus infection. Am J Epidemiol. 2022;191(9):1614\u20131625. doi: 10.1093\/aje\/kwac104.","DOI":"10.1093\/aje\/kwac104"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Weathers FW, Bovin MJ, Lee DJ et al. The clinician-administered PTSD scale for DSM\u20135 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess. 2018;30(3):383\u2013395. doi: 10.1037\/pas0000486.","DOI":"10.1037\/pas0000486"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Shiner B, Bateman D, Young-Xu Y et al. Comparing the stability of diagnosis in full vs. partial posttraumatic stress disorder. J Nerv Ment Dis. 2012;200(6):520\u2013525. doi: 10.1097\/NMD.0b013e318257c6da.","DOI":"10.1097\/NMD.0b013e318257c6da"},{"key":"ref27","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333. quiz 34\u201357."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Hooper LM, Stockton P, Krupnick JL, Green BL. Development, use, and psychometric properties of the trauma history questionnaire. J Loss Trauma. 2011;16(3):258\u2013283. doi: 10.1080\/15325024.2011.572035.","DOI":"10.1080\/15325024.2011.572035"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Dieperink M, Erbes C, Leskela J et al. Comparison of treatment for post-traumatic stress disorder among three department of veterans affairs medical centers. Mil Med. 2005;170(4):305\u2013308. doi: 10.7205\/milmed.170.4.305.","DOI":"10.7205\/milmed.170.4.305"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Bovin MJ, Marx BP, Weathers FW et al. Psychometric properties of the PTSD checklist for diagnostic and statistical manual of mental disorders-fifth edition (PCL-5) in veterans. Psychol Assess. 2016;28(11):1379\u20131391. doi: 10.1037\/pas0000254.","DOI":"10.1037\/pas0000254"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573\u2013583. doi: 10.1016\/S0006-3223(02)01866-8.","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"McCrea MA, Giacino JT, Barber J et al. Functional outcomes over the first year after moderate to severe traumatic brain injury in the prospective, longitudinal TRACK-TBI study. JAMA Neurol. 2021;78(8):982. doi: 10.1001\/jamaneurol.2021.2043.","DOI":"10.1001\/jamaneurol.2021.2043"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Herbers J, Miller R, Walther A et al. How to deal with non-detectable and outlying values in biomarker research: best practices and recommendations for univariate imputation approaches. Compr Psychoneuroendocrinology. 2021;7:100052. doi: 10.1016\/j.cpnec.2021.100052.","DOI":"10.1016\/j.cpnec.2021.100052"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Whitcomb BW, Schisterman EF. Assays with lower detection limits: implications for epidemiological investigations. Paediatr Perinat Epidemiol. 2008;22(6):597\u2013602. doi: 10.1111\/j.1365-3016.2008.00969.x.","DOI":"10.1111\/j.1365-3016.2008.00969.x"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Schnurr PP, Chard KM, Ruzek JI et al. Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among US veterans: a randomized clinical trial. JAMA Netw Open. 2022;5(1):e2136921. doi: 10.1001\/jamanetworkopen.2021.36921.","DOI":"10.1001\/jamanetworkopen.2021.36921"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Gola H, Engler H, Sommershof A et al. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry. 2013;13(1):40. doi: 10.1186\/1471-244X-13-40.","DOI":"10.1186\/1471-244X-13-40"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Buto PT, Shah A, Pearce BD et al. Association of systemic inflammation with posttraumatic stress disorder after a myocardial infarction. Brain Behav Immun Health. 2023;30:100629. doi: 10.1016\/j.bbih.2023.100629.","DOI":"10.1016\/j.bbih.2023.100629"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Fonseca MM, Davoli-Ferreira M, Santa-Cec\u00edlia F et al. IL-27 Counteracts neuropathic pain development through induction of IL-10. Front Immunol. 2020;10:3059. doi: 10.3389\/fimmu.2019.03059.","DOI":"10.3389\/fimmu.2019.03059"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:36:08Z","timestamp":1791315368000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/glecaprevir-pibrentasvir-for-post-traumatic-stress-disorder\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.15419","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}